OnKure Therapeutics (OKUR) Competitors $16.90 +0.02 (+0.12%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrends OKUR vs. ENTA, XBIT, ETON, CRBP, NKTX, TRVI, FULC, SCPH, NVCT, and GOSSShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Eton Pharmaceuticals (ETON), Corbus Pharmaceuticals (CRBP), Nkarta (NKTX), Trevi Therapeutics (TRVI), Fulcrum Therapeutics (FULC), scPharmaceuticals (SCPH), Nuvectis Pharma (NVCT), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry. OnKure Therapeutics vs. Enanta Pharmaceuticals XBiotech Eton Pharmaceuticals Corbus Pharmaceuticals Nkarta Trevi Therapeutics Fulcrum Therapeutics scPharmaceuticals Nuvectis Pharma Gossamer Bio OnKure Therapeutics (NASDAQ:OKUR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment. Does the MarketBeat Community favor OKUR or ENTA? Enanta Pharmaceuticals received 312 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 56.76% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOnKure TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesEnanta PharmaceuticalsOutperform Votes31556.76% Underperform Votes24043.24% Do analysts prefer OKUR or ENTA? OnKure Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 121.89%. Enanta Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 97.43%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe OnKure Therapeutics is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Enanta Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has preferable valuation & earnings, OKUR or ENTA? OnKure Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$77.39M-$12.20-1.39Enanta Pharmaceuticals$79.20M2.71-$133.82M-$5.45-1.86 Is OKUR or ENTA more profitable? OnKure Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -160.27%. OnKure Therapeutics' return on equity of -51.17% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -51.17% -47.11% Enanta Pharmaceuticals -160.27%-63.75%-27.09% Do insiders and institutionals hold more shares of OKUR or ENTA? 91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, OKUR or ENTA? OnKure Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Does the media favor OKUR or ENTA? In the previous week, OnKure Therapeutics had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for OnKure Therapeutics and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.62 beat OnKure Therapeutics' score of 0.01 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOnKure Therapeutics beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.45M$7.03B$5.37B$8.88BDividend YieldN/A8.03%5.06%4.03%P/E Ratio-1.3911.50127.4017.46Price / SalesN/A347.551,258.8592.75Price / CashN/A49.2239.3636.42Price / Book0.769.076.285.86Net Income-$77.39M$154.14M$119.59M$225.15M7 Day Performance-1.69%-2.23%-1.08%-0.90%1 Month Performance-9.58%7.49%3.63%3.70%1 Year PerformanceN/A37.73%36.55%26.40% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.2085 of 5 stars$16.90+0.1%$37.50+121.9%N/A$56.45MN/A-1.39N/AEarnings ReportNews CoverageENTAEnanta Pharmaceuticals4.075 of 5 stars$11.07-2.5%N/A+27.5%$234.56M$71.96M-2.03145Upcoming EarningsXBITXBiotech1.3526 of 5 stars$7.55+2.6%N/A+80.7%$230M$4.01M-6.51100ETONEton Pharmaceuticals3.1537 of 5 stars$8.78+1.3%N/A+196.1%$226.84M$31.38M-33.7720Analyst ForecastShort Interest ↓News CoverageCRBPCorbus Pharmaceuticals4.8207 of 5 stars$18.78+1.4%N/A+475.0%$226.19M$880,000.00-3.2340Short Interest ↓Analyst RevisionGap UpNKTXNkarta2.3298 of 5 stars$3.19-2.4%N/A+52.4%$225.08MN/A-1.59140Analyst ForecastHigh Trading VolumeTRVITrevi Therapeutics3.7011 of 5 stars$2.91+0.3%N/A+113.4%$223.68MN/A-6.6120Analyst RevisionFULCFulcrum Therapeutics3.4627 of 5 stars$3.49+0.3%N/A+2.6%$217.78M$81.63M-9.97100Analyst ForecastNews CoverageSCPHscPharmaceuticals4.0337 of 5 stars$4.21-2.8%N/A-21.5%$210.37M$13.59M-2.7030Analyst ForecastNews CoverageGap DownNVCTNuvectis Pharma3.0933 of 5 stars$10.81+29.6%N/A+27.8%$208.85MN/A-9.328News CoverageGap DownTrading HaltedHigh Trading VolumeGOSSGossamer Bio4.4915 of 5 stars$0.88-1.1%N/A+29.5%$198.83MN/A-2.25180Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies Enanta Pharmaceuticals Alternatives XBiotech Alternatives Eton Pharmaceuticals Alternatives Corbus Pharmaceuticals Alternatives Nkarta Alternatives Trevi Therapeutics Alternatives Fulcrum Therapeutics Alternatives scPharmaceuticals Alternatives Nuvectis Pharma Alternatives Gossamer Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OKUR) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
